A Simple Mineral That Helps Protect a Premature Baby's Brain — and What New Research Says About It

Plain-language coverage of a 2024 review combining seven trials (Jafarabady et al., BMC Pregnancy and Childbirth) on giving mothers magnesium before an early birth

When a baby is about to be born much too early, doctors can give the mother an intravenous drip of magnesium sulfate — a form of the same mineral found in many foods — in the hours before delivery. A 2024 review that pooled the results of seven clinical trials, involving more than 8,000 mothers and babies, found that this simple treatment lowered the chance that the child would later develop cerebral palsy by roughly a third, without changing the baby's chance of survival [1]. That finding held up even after a large, more recent trial had raised doubts.

Why This Matters

Being born early is common and consequential. Worldwide, a substantial share of all births happen before the pregnancy reaches full term, and prematurity is one of the leading reasons young children die or grow up with lasting health challenges [2]. Among the babies who survive, the developing brain is especially vulnerable, and premature birth raises the risk of difficulties with movement, thinking, learning, and behavior later in life [3]. One of the most serious of these is cerebral palsy, a group of lifelong conditions that affect movement, posture, and muscle control. Anything that safely lowers that risk is therefore enormously valuable to families.

How Families and Doctors Used to Face This Problem

For most of its history in pregnancy, magnesium sulfate was used for completely different reasons — to try to slow down early labor and to treat a dangerous blood-pressure complication called pre-eclampsia. As far back as 1977, doctors were already studying magnesium as a way to hold off premature labor [4]. For a long time, when a baby was on the way far too soon, there was very little that could be offered specifically to shield that baby's brain; families could only hope for the best. The idea that magnesium itself might protect the brain — rather than just delay birth — came later, and it had to be tested carefully before anyone could recommend it.

That testing took years. The turning point came from large, carefully designed studies, most importantly a major American trial published in 2008 that found fewer cases of moderate-to-severe cerebral palsy among surviving children whose mothers had received magnesium [5]. When researchers combined that trial with earlier ones, the protective pattern became clearer: in one influential summary, cerebral palsy dropped from about 5.6% of children to about 3.9% with magnesium [6]. A 2017 analysis that pooled the original data from several trials gave doctors enough confidence to write magnesium into official guidelines [7], and major medical organizations began recommending it as a standard part of care when a very early birth is expected [8].

A New Trial That Raised Questions

Science rarely moves in a straight line. In 2023, a carefully run trial called MAGENTA tested magnesium in mothers who were a little further along — between 30 and 34 weeks of pregnancy — and found that it did not improve the chances of a child surviving free of cerebral palsy [9]. This understandably worried both doctors and parents: had the treatment been oversold? The 2024 review at the center of this article was created specifically to answer that question by adding the new, more skeptical trial into the pool with all the others and seeing what the combined picture showed [1].

What the Researchers Did and Found

The research team gathered every high-quality randomized trial they could find — the most reliable kind of study, in which mothers are assigned by chance to receive either magnesium or a dummy (placebo) infusion — searching the major medical databases through late 2023 [1]. Seven trials qualified, together including 8,171 mothers and their babies, who were followed for one to two years after birth. Most trials gave a starting dose of about 4 grams of magnesium into a vein, with a couple using slightly higher amounts [5].

The combined results were encouraging. Babies whose mothers received magnesium were significantly less likely to have neurological problems, mainly cerebral palsy — a reduction of about 30% [1]. Just as importantly, the trials all pointed in the same direction, meaning the benefit was consistent rather than a fluke from one unusual study. Magnesium did not change whether babies survived — it neither raised nor lowered the chance of death [1]. And whether trials used a slightly lower or higher dose made no measurable difference to the result. In short, even after the doubt-raising MAGENTA trial [9] was thrown into the mix, the brain-protecting benefit was still there.

Why a Mineral Given to the Mother Helps the Baby

It may seem surprising that giving a mineral to a mother can protect her unborn baby's brain. Scientists believe magnesium works in several ways: it appears to calm overactive nerve signaling that can damage fragile brain cells, reduce inflammation, and steady blood flow to the developing brain [10]. Brain-imaging studies add support — for example, premature babies exposed to magnesium before birth have shown less bleeding in a part of the brain called the cerebellum [11]. The magnesium crosses from the mother's bloodstream to the baby's in the crucial hours around birth, when the early brain is most at risk.

What This Means for Families

If you are facing a possible early delivery, this research supports what many hospitals already do: offering magnesium to help protect your baby's brain. It is helpful to understand the treatment honestly. Magnesium lowers the risk of cerebral palsy — it does not guarantee that a child will be unaffected, and it does not make the baby more likely to survive [1]. The benefit appears strongest for the earliest, most fragile babies and smaller for those closer to 32 to 34 weeks, which is part of why experts still discuss exactly when to use it [7]. The treatment is given with careful monitoring of the mother, because too much magnesium can cause side effects, and the medical team watches for these throughout.

What "30% Lower Risk" Really Means

It is worth slowing down on that headline number, because relative figures can be confusing. A 30% reduction does not mean 30 out of 100 babies are saved from cerebral palsy. It means that whatever a baby's starting risk was, magnesium lowers it by roughly a third. For the most premature babies, whose starting risk is higher, that translates into a larger real-world benefit; for babies closer to 34 weeks, whose starting risk is already lower, the same percentage produces a smaller actual change. This is exactly why the benefit looked strong in the earlier trials of very early babies and looked weaker in the MAGENTA trial of slightly older ones [9] — and why combining all the trials still showed a clear overall benefit while leaving room for honest debate about the latest weeks [1]. Understanding the number this way can help families have a realistic, hopeful conversation with their care team rather than expecting a guarantee.

It also helps to know that magnesium is not a new or experimental drug. It has been used in pregnancy for decades and is inexpensive and widely available, which is part of why guideline groups around the world embraced it once the evidence matured [8]. The infusion is given to the mother, usually started when delivery is expected soon, and the medical team keeps a close eye on her — checking reflexes, breathing, and how she feels — because the same mineral that protects the baby can cause uncomfortable side effects in the mother if levels climb too high. These are familiar, manageable parts of care, and the combined trials found no increase in the risk of a baby dying, which is an important reassurance about safety [1].

What Researchers Are Working On Next

The big open questions are now clearer than ever. Scientists want to pin down the precise point in pregnancy at which magnesium stops being worth giving, since the doubt raised by the MAGENTA trial centered on the later weeks [9]. They also want to find the best dose, and — perhaps most important for families — to follow these children into their school years to see whether the early protection against cerebral palsy translates into real differences in how children move, learn, and thrive over time [3]. One more gap stands out: most of these trials were done in wealthier countries, even though the majority of premature births happen in lower-income parts of the world, so more research is needed to make sure every family can benefit [2]. For now, the weight of the evidence remains reassuring: a simple, inexpensive mineral, given at the right moment, gives a premature baby's brain a meaningful measure of protection [1].

  1. Jafarabady K, Shafiee A, Eshraghi N, Salehi SA, Mohammadi I, Rajai S, Zareian Z, Movahed F, Bakhtiyari M. Magnesium sulfate for fetal neuroprotection in preterm pregnancy: a meta-analysis of randomized controlled trials. BMC Pregnancy Childbirth. 2024;24(1):519. doi:10.1186/s12884-024-06703-9 ↩
  2. Cao G, Liu J, Liu M. Global, regional, and national incidence and mortality of neonatal preterm birth, 1990–2019. JAMA Pediatr. 2022;176(8):787–796. doi:10.1001/jamapediatrics.2022.1622 ↩
  3. Ream MA, Lehwald L. Neurologic consequences of preterm birth. Curr Neurol Neurosci Rep. 2018;18(8):48. doi:10.1007/s11910-018-0862-2 ↩
  4. Steer CM, Petrie RH. A comparison of magnesium sulfate and alcohol for the prevention of premature labor. Am J Obstet Gynecol. 1977;129(1):1–4. doi:10.1016/0002-9378(77)90808-090808-0) ↩
  5. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359(9):895–905. doi:10.1056/NEJMoa0801187 ↩
  6. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009;200(6):595–609. doi:10.1016/j.ajog.2009.04.005 ↩
  7. Crowther CA, Middleton PF, Voysey M, Askie L, Duley L, Pryde PG, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med. 2017;14(10):e1002398. doi:10.1371/journal.pmed.1002398 ↩
  8. Magee LA, De Silva DA, Sawchuck D, Synnes A, von Dadelszen P. No. 376-Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can. 2019;41(4):505–522. doi:10.1016/j.jogc.2018.09.018 ↩
  9. Crowther CA, Ashwood P, Middleton PF, McPhee A, Tran T, Harding JE. Prenatal intravenous magnesium at 30–34 weeks' gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial. JAMA. 2023;330(7):603–614. doi:10.1001/jama.2023.12357 ↩
  10. Bachnas MA, Akbar MIA, Dachlan EG, Dekker G. The role of magnesium sulfate (MgSO4) in fetal neuroprotection. J Matern Fetal Neonatal Med. 2021;34(6):966–978. doi:10.1080/14767058.2019.1619688 ↩
  11. Gano D, Ho M-L, Partridge JC, Glass HC, Xu D, Barkovich AJ, et al. Antenatal exposure to magnesium sulfate is associated with reduced cerebellar hemorrhage in preterm newborns. J Pediatr. 2016;178:68–74. doi:10.1016/j.jpeds.2016.06.053 ↩